Identification and management of familial breast cancer in Austria

References

[1] Welcsh PL, King MC. BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Hum Mol Genet. 2001;10:705–13.10.1093/hmg/10.7.705Suche in Google Scholar PubMed

[2] Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The breast cancer linkage consortium. Am J Hum Genet. 1998;62:676–89.10.1086/301749Suche in Google Scholar PubMed PubMed Central

[3] Marsh DJ, Howell VM. The use of denaturing high performance liquid chromatography (DHPLC) for mutation scanning of hereditary cancer genes. Methods Mol Biol. 2010;653:133–45.10.1007/978-1-60761-759-4_8Suche in Google Scholar PubMed

[4] Ekstrøm PO, Bjørge T, Dørum A, Longva AS, Heintz KM, Warren DJ, et al. Determination of hereditary mutations in the BRCA1 gene using archived serum samples and capillary electrophoresis. Anal Chem. 2004;76:4406–9.10.1021/ac049788kSuche in Google Scholar PubMed

[5] Wallace AJ. New challenges for BRCA testing: a view from the diagnostic laboratory. Eur J Hum Genet. 2016;24:S10–8.10.1038/ejhg.2016.94Suche in Google Scholar PubMed PubMed Central

[6] Kozlowski P, Jasinska AJ, Kwiatkowski DJ. New applications and developments in the use of multiplex ligation-dependent probe amplification. Electrophoresis. 2008;29:4627–36.10.1002/elps.200800126Suche in Google Scholar PubMed

[7] Singer CF, Tea MK, Pristauz G, Hubalek M, Rappaport C, Riedl CC, et al. Clinical practice guideline for the prevention and early detection of breast and ovarian cancer in women from HBOC (hereditary breast and ovarian cancer) families. Wien Klin Wochenschr. 2015;127:981–6.10.1007/s00508-015-0880-xSuche in Google Scholar PubMed

[8] George A, Kaye S, Banerjee S. Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer. Nat Rev Clin Oncol. 2017;14:284–96.10.1038/nrclinonc.2016.191Suche in Google Scholar PubMed

[9] Passaperuma K, Warner E, Causer PA, Hill KA, Messner S, Wong JW, et al. Long-term results of screening with magnetic resonance imaging in women with BRCA mutations. Br J Cancer. 2012;107:24–30.10.1038/bjc.2012.204Suche in Google Scholar PubMed PubMed Central

[10] Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72:1117–30.10.1086/375033Suche in Google Scholar PubMed PubMed Central

[11] Finch A, Beiner M, Lubinski J, Lynch HT, Moller P, Rosen B, et al. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. J Am Med Assoc. 2006;296:185–92.10.1001/jama.296.2.185Suche in Google Scholar PubMed

[12] Bermejo-Pérez MJ, Márquez-Calderón S, Llanos-Méndez A. Effectiveness of preventive interventions in BRCA1/2 gene mutation carriers: a systematic review. Int J Cancer. 2007;121:225–31.10.1002/ijc.22817Suche in Google Scholar PubMed

[13] Metcalfe K, Lynch HT, Foulkes WD, Tung N, Kim-Sing C, Olopade OI, et al. Effect of oophorectomy on survival after breast cancer in BRCA1 and BRCA2 mutation carriers. JAMA Oncol. 2015;1:306–13.10.1001/jamaoncol.2015.0658Suche in Google Scholar PubMed

[14] Riedl CC, Luft N, Bernhart C, Weber M, Bernathova M, Tea MK, et al. Triple-modality screening trial for familial breast cancer underlines the importance of magnetic resonance imaging and questions the role of mammography and ultrasound regardless of patient mutation status, age, and breast density. J Clin Oncol. 2015;33:1128–35.10.1200/JCO.2014.56.8626Suche in Google Scholar PubMed PubMed Central

[15] Gschwantler-Kaulich D, Schrenk P, Bjelic-Radisic V, Unterrieder K, Leser C, Fink-Retter A, et al. Mesh versus acellular dermal matrix in immediate implant-based breast reconstruction - A prospective randomized trial. Eur J Surg Oncol. 2016;42:665–71.10.1016/j.ejso.2016.02.007Suche in Google Scholar PubMed

[16] Singer CF, Muhr D, Rappaport C, Tea MK, Gschwantler-Kaulich D, Fink-Retter A, et al. Clinical implications of genetic testing for BRCA1 and BRCA2 mutations in Austria. Clin Genet. 2014;85:72–5.10.1111/cge.12216Suche in Google Scholar PubMed

[17] Rebbeck TR, Friebel T, Lynch HT, Neuhausen SL, van ’t Veer L, Garber JE, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2004;22:1055–62.10.1200/JCO.2004.04.188Suche in Google Scholar PubMed

[18] Eisen A, Lubinski J, Klijn J, Moller P, Lynch HT, Offit K, et al. Breast cancer risk following oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol. 2005;23:7491–6.10.1200/JCO.2004.00.7138Suche in Google Scholar PubMed